Viking Therapeutics, Inc.
VKTXNext catalyst
VK2735
Weight Loss
Get an email about VKTX's next catalysts
Track Viking Therapeutics (VKTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
VK2735 Phase 3 Est. Readout
Primary completion for VK2735 trial (NCT07104383) in Weight Loss
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Viking Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Viking Therapeutics, Inc.'s (VKTX) pipeline across Phase 3, Phase 2. Its lead program is VK2735 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Viking Therapeutics, Inc.'s next FDA catalyst?→
Viking Therapeutics, Inc.'s (VKTX) next tracked catalyst is a Phase 3 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VKTX biotech catalysts?→
Add VKTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Viking Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.